TAK-632

N/A

Report date: 2022/02/15 16:47:25

NME

Base Information

Drug NameTAK-632

Drug Alias NameTAK-632

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionReceptor-interacting serine/threonine-protein kinase 1 inhibitorsSerine/threonine-protein kinase RIPK3 inhibitorsRAF serine/threonine protein kinase inhibitors

TargetsReceptor-interacting serine/threonine-protein kinase 1Serine/threonine-protein kinase RIPK3RAF serine/threonine protein kinase

Therapy Area/IndicationsMelanoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryJapan

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesTakeda Pharmaceutical Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesTakeda Pharmaceutical Co Ltd

Inactive CompaniesN/A

Active IndicationsMelanoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A